Salud financiera de hoja de balance de WuXi Biologics (Cayman)
Salud financiera controles de criterios 5/6
WuXi Biologics (Cayman) tiene un patrimonio de accionistas total de CN¥44.6B y una deuda total de CN¥2.2B, lo que sitúa su ratio deuda-patrimonio en 4.8%. Sus activos y pasivos totales son CN¥56.1B y CN¥11.5B respectivamente. El BAIT de WuXi Biologics (Cayman) es de CN¥3.5B, por lo que su ratio de cobertura de intereses es de -18.3. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥9.5B.
Información clave
4.8%
Ratio deuda-patrimonio
CN¥2.16b
Deuda
| Ratio de cobertura de intereses | -18.3x |
| Efectivo | CN¥9.53b |
| Patrimonio | CN¥44.64b |
| Total pasivo | CN¥11.46b |
| Activos totales | CN¥56.11b |
Actualizaciones recientes sobre salud financiera
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Recent updates
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar
Sep 26WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (CN¥19.8B) de 2269 superan a sus pasivos a corto plazo (CN¥6.8B).
Pasivo a largo plazo: Los activos a corto plazo de 2269 (CN¥19.8B) superan a sus pasivos a largo plazo (CN¥4.7B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 2269 tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de 2269 ha crecido de 0% a 4.8% en los últimos 5 años.
Cobertura de la deuda: La deuda de 2269 está bien cubierta por el flujo de caja operativo (149.3%).
Cobertura de intereses: 2269 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.